Inference of ceftobiprole susceptibility through surrogate testing of ceftaroline
Journal of Clinical Microbiology · 2026
DOI: 10.1128/jcm.01706-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Microbiology, 2026. Verfasst von Helio S Sader und 4 weiteren Autor:innen. Beteiligte Einrichtung: Element Iowa City (JMI Laboratories), North Liberty, Iowa, USA. Hauptthemen laut MEDLINE: Cephalosporins, Anti-Bacterial Agents, Bacteria. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Ceftobiprole is an advanced-generation cephalosporin active against methicillin-resistant Staphylococcus aureus and other clinically relevant bacteria. Ceftobiprole was recently (April 2024) approved for clinical use in the United States, but susceptibility testing is still not available on commercial automated susceptibility testing systems. We evaluated the accuracy and error rates when using susceptibility to ceftaroline to predict susceptibility to ceftobiprole. A total of 42,363 clinical isolates were collected through the SENTRY Antimicrobial Surveillance Program from 34 US medical centers in 2016–2020 and tested against ceftobiprole and ceftaroline by broth microdilution method. The accuracy of the surrogate test (susceptibility to ceftaroline) was defined as the percentage of isolates susceptible to ceftobiprole among ceftaroline-susceptible isolates. Minor error rate was then defined as the percentage of ceftobiprole-intermediate among ceftaroline-susceptible isolates, and very major error was defined as the percentage of ceftobiprole-resistant isolates among ceftaroline-susceptible isolates. The accuracy of the surrogate test to predict susceptibility to ceftobiprole was >99% for S. aureus (99.98%), including methicillin-resistant S. aureus (99.95%), Streptococcus pneumoniae (99.48%), β-hemolytic streptococci (100.00%), Escherichia coli (99.97%), and Klebsiella pneumoniae (99.91%). Accuracy was also extremely high for Haemophilus spp. (98.86%) and Enterobacterales (98.73%). Minor error rates were
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Element Iowa City (JMI Laboratories), North Liberty, Iowa, USA.
- Innoviva Specialty Pharmaceuticals, Waltham, Massachusetts, USA.
ORCID-Profile: Helio S Sader, Rodrigo E Mendes
Zitieren
APA
Sader, H. S., Mendes, R. E., Nicolau, D. P., Zappas, K. K., & Castanheira, M. (2026). Inference of ceftobiprole susceptibility through surrogate testing of ceftaroline. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.01706-25
Vancouver
Sader HS, Mendes RE, Nicolau DP, Zappas KK, Castanheira M. Inference of ceftobiprole susceptibility through surrogate testing of ceftaroline. Journal of Clinical Microbiology. 2026. doi:10.1128/jcm.01706-25
BibTeX
@article{Sader2026,
author = {Sader, Helio S and Mendes, Rodrigo E and Nicolau, David P and Zappas, Kristie K and Castanheira, Mariana},
title = {Inference of ceftobiprole susceptibility through surrogate testing of ceftaroline},
journal = {Journal of Clinical Microbiology},
year = {2026},
doi = {10.1128/jcm.01706-25}
}
EUVIMED